RT Journal Article
T1 New Formulations Loading Caspofungin for Topical Therapy of Vulvovaginal Candidiasis
A1 Perez-Gonzalez, Noelia
A1 Bozal-de Febrer, Nuria
A1 Calpena-Campmany, Ana C.
A1 Nardi-Ricart, Anna
A1 Rodriguez-Lagunas, Maria J.
A1 Morales-Molina, Jose A.
A1 Soriano-Ruiz, Jose L.
A1 Fernandez-Campos, Francisco
A1 Clares-Naveros, Beatriz
K1 vulvovaginal candidiasis
K1 antifungal therapy
K1 caspofungin
K1 vaginal mucosal delivery
K1 mucoadhesive hydrogel
K1 thermoreversible hydrogel
K1 Systemic antifungal agents
K1 Chitosan derivatives
K1 Sustained-release
K1 Hydrogels
K1 Nanocapsules
K1 Delivery
K1 F127
K1 Gel
K1 Pharmacokinetics
K1 Mucoadhesion
AB Vulvovaginal candidiasis (VVC) poses a significant problem worldwide affecting women from all strata of society. It is manifested as changes in vaginal discharge, irritation, itching and stinging sensation. Although most patients respond to topical treatment, there is still a need for increase the therapeutic arsenal due to resistances to anti-infective agents. The present study was designed to develop and characterize three hydrogels of chitosan (CTS), Poloxamer 407 (P407) and a combination of both containing 2% caspofungin (CSP) for the vaginal treatment of VVC. CTS was used by its mucoadhesive properties and P407 was used to exploit potential advantages related to increasing drug concentration in order to provide a local effect. The formulations were physically, mechanically and morphologically characterized. Drug release profile and ex vivo vaginal permeation studies were performed. Antifungal efficacy against different strains of Candida spp. was also evaluated. In addition, tolerance of formulations was studied by histological analysis. Results confirmed that CSP hydrogels could be proposed as promising candidates for the treatment of VVC.
PB Mdpi
YR 2021
FD 2021-12-01
LK https://hdl.handle.net/10668/24940
UL https://hdl.handle.net/10668/24940
LA en
DS RISalud
RD Apr 8, 2025